TCA
AYTU icon

Transcend Capital Advisors’s AYTU BioPharma AYTU Stock Holding History

Transcend Capital Advisors’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-50
Closed -$12K – 377
2020
Q3 		$12K Buy
+50
New +$12.9K ﹤0.01% 268

Other funds holding AYTU

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PSC
Piper Sandler & Co Minneapolis, Minnesota $102M AUM 0.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Transcend Capital Advisors's AYTU Position: Q4 2020 in Review

Transcend Capital Advisors sold out of AYTU BioPharma (AYTU) in Q4 2020, closing a stake of 50 shares — an estimated $12K sold.

Transcend Capital Advisors first reported a position in AYTU in Q3 2020 and held it in 1 quarter. The position peaked at $12K in Q3 2020. 42 funds tracked by Wall St. Rank hold AYTU as of Q4 2020.

  • Transcend Capital Advisors reported no remaining AYTU BioPharma position as of Q4 2020 after selling out during the quarter.
  • Transcend Capital Advisors sold 50 AYTU BioPharma shares in Q4 2020, an estimated $12K.
  • Transcend Capital Advisors first reported a position in AYTU BioPharma in Q3 2020 and held it in 1 quarter.
  • Transcend Capital Advisors's AYTU BioPharma position peaked at $12K in Q3 2020.
  • 42 funds tracked by Wall St. Rank held AYTU BioPharma as of Q4 2020.

Based on Transcend Capital Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.